EML4-ALK (Eex13Aex20), Active (A19-19G)

EML4-ALK (Eex13Aex20), Active (A19-19G)

  • $259.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :Recombinant human fusion protein EML4 (1-496)-ALK (1058-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.

Species :Human

Tag :GST tag

Expression System:Sf9 insect cells using baculovirus

Sequence :1-496 (EML4) - 1058-end (ALK)

Genbank Number :AB274722

Specific Activity :Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.

Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.

Storage, Stability and Shipping :Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Applications :Kinase Assay

Molecular Weight :~150 kDa

Gene Aliases :EML4: C2orf2, EMAPL4
ALK: ALK (Ki-1), CD246, NBLST3, TFG/ALK

Scientific Background :ALK or CD246 is a receptor tyrosine kinase, which belongs to the insulin receptor superfamily, which comprises an extracellular domain, a hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. CD246 plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. ALK-positive neoplasms represent a distinct entity because the morphology of the tumors is often neither anaplastic nor large cell and the tumors should be referred to as ALK lymphomas (1). CD246 has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. EML4-ALK mutations in lung cancer confer resistance to ALK inhibitors (2).

References :
1. Benharroch, D.et.al : ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 91: 2076-2084, 1998.

2. Choi, Y. L. et.al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. New Eng. J. Med. 363: 1734-1739, 2010.

Product Sheets (By Lot #) :

A1134-3.pdf

G1414-3.pdf

E3020-7.pdf

Research Areas :Angiogenesis, Cancer, Cellular Stress, Receptor Tyrosine Kinases, Ser/Thr Kinases, Cancer, Receptor Tyrosine Kinases